- Home
- SBLK vs DNLI Comparison
SBLK vs DNLI Comparison
Compare SBLK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- DNLI
- Stock Information
- Founded
- SBLK 2006
- DNLI 2013
- Country
- SBLK Greece
- DNLI United States
- Employees
- SBLK N/A
- DNLI N/A
- Industry
- SBLK Marine Transportation
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBLK Consumer Discretionary
- DNLI Health Care
- Exchange
- SBLK Nasdaq
- DNLI Nasdaq
- Market Cap
- SBLK 2.1B
- DNLI 2.5B
- IPO Year
- SBLK N/A
- DNLI 2017
- Fundamental
- Price
- SBLK $19.06
- DNLI $18.15
- Analyst Decision
- SBLK Strong Buy
- DNLI Strong Buy
- Analyst Count
- SBLK 1
- DNLI 13
- Target Price
- SBLK $22.00
- DNLI $32.64
- AVG Volume (30 Days)
- SBLK 889.6K
- DNLI 1.5M
- Earning Date
- SBLK 11-18-2025
- DNLI 11-06-2025
- Dividend Yield
- SBLK 1.06%
- DNLI N/A
- EPS Growth
- SBLK N/A
- DNLI N/A
- EPS
- SBLK 0.53
- DNLI N/A
- Revenue
- SBLK $1,050,829,000.00
- DNLI N/A
- Revenue This Year
- SBLK N/A
- DNLI N/A
- Revenue Next Year
- SBLK $19.06
- DNLI $94,232.03
- P/E Ratio
- SBLK $36.45
- DNLI N/A
- Revenue Growth
- SBLK N/A
- DNLI N/A
- 52 Week Low
- SBLK $12.06
- DNLI $10.57
- 52 Week High
- SBLK $19.99
- DNLI $26.18
- Technical
- Relative Strength Index (RSI)
- SBLK 56.56
- DNLI 64.30
- Support Level
- SBLK $18.74
- DNLI $16.85
- Resistance Level
- SBLK $19.61
- DNLI $18.21
- Average True Range (ATR)
- SBLK 0.49
- DNLI 1.11
- MACD
- SBLK 0.06
- DNLI 0.13
- Stochastic Oscillator
- SBLK 69.81
- DNLI 88.08
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.